Evidence map›Paper›PMID 39728437›Full record

ArticleMetabolites2024

Longitudinal Metabolomics Reveals Metabolic Dysregulation Dynamics in Patients with Severe COVID-19.

Ryo Uchimido, Kenjiro Kami, Hiroyuki Yamamoto, Ryo Yokoe, Issei Tsuchiya, Yoko Nukui, Yuki Goto, Mariko Hanafusa, Takeo Fujiwara, Kenji Wakabayashi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Metabolites, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ryo UchimidoDepartment of Intensive Care Medicine, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo City 113-8510, Japan.ORCID 0000-0002-5059-616X
Kenjiro KamiHuman Metabolome Technologies, Inc., 246-2 Mizukami Kakuganji, Tsuruoka City 997-0052, Japan.
Hiroyuki YamamotoHuman Metabolome Technologies, Inc., 246-2 Mizukami Kakuganji, Tsuruoka City 997-0052, Japan.
Ryo YokoeDepartment of Intensive Care Medicine, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo City 113-8510, Japan.
Issei TsuchiyaDepartment of Intensive Care Medicine, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo City 113-8510, Japan.
Yoko NukuiDepartment of Infection Control and Laboratory Medicine, Kyoto Prefectural University of Medicine, Kamigyo-ku Kajii-cho, Kawaramachi-Hirokoji, Kyoto 602-8566, Japan.ORCID 0000-0002-6123-5212
Yuki GotoDepartment of Tokyo Metropolitan Health Policy Advisement, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo City 113-8519, Japan.
Mariko HanafusaDivision of Cohort Research, National Cancer Center Institute for Cancer Control, Tokyo 104-0045, Japan.ORCID 0000-0003-1038-7715
Takeo FujiwaraDepartment of Public Health, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo City 113-8519, Japan.ORCID 0000-0002-1074-3954
Kenji WakabayashiDepartment of Intensive Care Medicine, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo City 113-8510, Japan.ORCID 0000-0001-5332-6192

Funding

Human Metabolome Technologies, Inc. 21MC100211Japan Society for the Promotion of Science 21K09067
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

longitudinal metabolic dysregulationsevere COVID-19

Identifiers

PMID39728437
PMCPMC11676849

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.